ADMA Biologics Inc (NASDAQ:ADMA) Stock Holdings Lifted by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 47.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,448,253 shares of the biotechnology company’s stock after purchasing an additional 786,567 shares during the quarter. Vanguard Group Inc.’s holdings in ADMA Biologics were worth $9,474,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ADMA. BlackRock Inc. raised its stake in ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock valued at $7,343,000 after purchasing an additional 919,260 shares during the period. A.R.T. Advisors LLC grew its holdings in shares of ADMA Biologics by 272.6% during the 2nd quarter. A.R.T. Advisors LLC now owns 70,665 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 51,700 shares in the last quarter. Ardsley Advisory Partners LP grew its holdings in shares of ADMA Biologics by 67.4% during the 2nd quarter. Ardsley Advisory Partners LP now owns 102,608 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 41,308 shares in the last quarter. Northern Trust Corp grew its holdings in shares of ADMA Biologics by 14.4% during the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 37,677 shares in the last quarter. Finally, H D Vest Advisory Services grew its holdings in shares of ADMA Biologics by 35.0% during the 2nd quarter. H D Vest Advisory Services now owns 135,050 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 35,000 shares in the last quarter. 59.07% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ADMA traded down $0.12 during midday trading on Thursday, reaching $4.59. 13,605 shares of the company were exchanged, compared to its average volume of 787,860. The firm has a market cap of $277.02 million, a PE ratio of -3.19 and a beta of 2.71. ADMA Biologics Inc has a fifty-two week low of $2.08 and a fifty-two week high of $6.31. The stock has a fifty day simple moving average of $4.62 and a two-hundred day simple moving average of $4.27. The company has a quick ratio of 7.93, a current ratio of 10.26 and a debt-to-equity ratio of 1.79.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $4.36 million. As a group, analysts forecast that ADMA Biologics Inc will post -0.95 earnings per share for the current year.

ADMA has been the topic of several research analyst reports. ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Friday, September 20th. Maxim Group set a $12.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a report on Monday. BidaskClub upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 19th. Finally, Dawson James cut shares of ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $10.20.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: How can you know how many shares are floating?

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.